BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 21878042)

  • 1. An overview of candesartan in clinical practice.
    Khawaja Z; Wilcox CS
    Expert Rev Cardiovasc Ther; 2011 Aug; 9(8):975-82. PubMed ID: 21878042
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Management of hypertension with fixed dose combinations of candesartan cilexetil and hydrochlorothiazide: patient perspectives and clinical utility.
    Mengden T; Uen S; Bramlage P
    Vasc Health Risk Manag; 2009; 5():1043-58. PubMed ID: 20057897
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Candesartan plus hydrochlorothiazide: an overview of its use and efficacy.
    Mugellini A; Nieswandt V
    Expert Opin Pharmacother; 2012 Dec; 13(18):2699-709. PubMed ID: 23170938
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Importance of a fixed combination of AT1-receptor blockade and hydrochlorothiazide for blood pressure lowering in cardiac risk patients. A postmarketing surveillance study with candesartan/HCTZ].
    Bramlage P; Schönrock E; Odoj P; Wolf WP; Funken C
    MMW Fortschr Med; 2008 Feb; 150(6):40. PubMed ID: 18323344
    [No Abstract]   [Full Text] [Related]  

  • 5. Rationale for triple fixed-dose combination therapy with an angiotensin II receptor blocker, a calcium channel blocker, and a thiazide diuretic.
    Volpe M; Tocci G
    Vasc Health Risk Manag; 2012; 8():371-80. PubMed ID: 22745561
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of blood pressure lowering, cholesterol lowering and their combination in Asians and non-Asians in those without cardiovascular disease: an analysis of the HOPE 3 study.
    Pais P; Jung H; Dans A; Zhu J; Liu L; Kamath D; Bosch J; Lonn E; Yusuf S
    Eur J Prev Cardiol; 2019 May; 26(7):681-697. PubMed ID: 30537846
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Candesartan cilexetil/hydrochlorothiazide treatment in high-risk patients with type 2 diabetes mellitus and microalbuminuria: the CHILI T2D study.
    Ketelhut R; Bramlage P
    Clin Drug Investig; 2010; 30(5):301-11. PubMed ID: 20384386
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ARB-based single-pill platform to guide a practical therapeutic approach to hypertensive patients.
    Volpe M; de la Sierra A; Kreutz R; Laurent S; Manolis AJ
    High Blood Press Cardiovasc Prev; 2014 Jun; 21(2):137-47. PubMed ID: 24532183
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [AT-1 blockers are different in their effects. The forgetful patients begin to notice it especially].
    MMW Fortschr Med; 2003 Apr; 145(15):62. PubMed ID: 15104271
    [No Abstract]   [Full Text] [Related]  

  • 10. The X-cellent Study.
    Safar ME
    Am J Hypertens; 2006 Jan; 19(1):8-9. PubMed ID: 16461182
    [No Abstract]   [Full Text] [Related]  

  • 11. Candesartan cilexetil/hydrochlorothiazide combination treatment versus high-dose candesartan cilexetil monotherapy in patients with mild to moderate cardiovascular risk (CHILI Triple T).
    Bönner G; Landers B; Bramlage P
    Vasc Health Risk Manag; 2011; 7():85-95. PubMed ID: 21415922
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low dose of hydrochlorothiazide, in combination with angiotensin receptor blocker, reduces blood pressure effectively without adverse effect on glucose and lipid profiles.
    Fujiwara W; Izawa H; Ukai G; Yokoi H; Mukaide D; Kinoshita K; Morimoto S; Ishii J; Ozaki Y; Nomura M
    Heart Vessels; 2013 May; 28(3):316-22. PubMed ID: 22447467
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Indapamide SR versus candesartan and amlodipine in hypertension: the X-CELLENT Study.
    London G; Schmieder R; Calvo C; Asmar R
    Am J Hypertens; 2006 Jan; 19(1):113-21. PubMed ID: 16461202
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Candesartan cilexetil--a review of effects on cardiovascular complications in hypertension and chronic heart failure.
    Meredith PA
    Curr Med Res Opin; 2007 Jul; 23(7):1693-705. PubMed ID: 17588300
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [First fixed combination of sartan and high-dosage diuretic. A strong duo against high blood pressure].
    MMW Fortschr Med; 2004 Apr; 146(14):45. PubMed ID: 15344757
    [No Abstract]   [Full Text] [Related]  

  • 16. Real-world effectiveness of amlodipine/valsartan and amlodipine/valsartan/hydrochlorothiazide in high-risk patients and other subgroups.
    Assaad-Khalil SH; Najem R; Sison J; Kitchlew AR; Cho B; Ueng KC; DiTommaso S; Shete A
    Vasc Health Risk Manag; 2015; 11():71-8. PubMed ID: 25653536
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lowering blood pressure in acute stroke: the SCAST trial.
    Hankey GJ
    Lancet; 2011 Feb; 377(9767):696-8. PubMed ID: 21316753
    [No Abstract]   [Full Text] [Related]  

  • 18. Efficacy of fixed-dose combination therapy in the treatment of patients with hypertension: focus on amlodipine/valsartan.
    da Silva PM
    Clin Drug Investig; 2010; 30(9):625-41. PubMed ID: 20626210
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antihypertensive efficacy and tolerability of candesartan-hydrochlorothiazide 32/12.5 mg and 32/25 mg in patients not optimally controlled with candesartan monotherapy.
    Bönner G;
    Blood Press Suppl; 2008 Dec; 2():22-30. PubMed ID: 19203019
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exforge HCT.
    Med Lett Drugs Ther; 2009 Jun; 51(1314):47. PubMed ID: 19528888
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.